Novo Nordisk creates AI division to help novel drug development

A new center in Seattle, US, will discover and develop new drugs using artificial intelligence. Recruitment for the new unit has begun.

Photo: Novo Nordisk / PR

The use of artificial intelligence (AI) is gaining popularity within the healthcare sector, where the technology is used to optimize hospital scheduling, indentify at-risk patients, support decision-making tools and more.

Novo Nordisk has now opened its eyes to the potential of AIs as a stepping stone in novel drug development – a potential so great that the Danish pharmaceutical giant is now establishing a center dedicated to this work.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs